scholarly journals OA12.03 Initial Reporting of NRG-LU001, Randomized Phase II Trial of Concurrent Chemoradiotherapy +/- Metformin HCL in Locally Advanced NSCLC

2019 ◽  
Vol 14 (10) ◽  
pp. S237-S238
Author(s):  
H. Skinner ◽  
C. Hu ◽  
T. Tsakiridis ◽  
R. Santana-Davila ◽  
B. Lu ◽  
...  
Keyword(s):  
Phase Ii ◽  
Concurrent Chemoradiotherapy ◽  
Advanced Nsclc ◽  
Phase Ii Trial ◽  
Locally Advanced ◽  
Randomized Phase Ii ◽  
Locally Advanced Nsclc ◽  
Metformin Hcl

scholarly journals Randomized Phase II Trial Comparing CDDP+TS-1+TRT and CDDP+DTX+TRT in Locally Advanced NSCLC (TORG1018)

2017 ◽  
Vol 28 ◽  
pp. ix83
Author(s):  
Makiko Yomota ◽  
Yukio Hosomi ◽  
Tsuneo Shimokawa ◽  
Hiroaki Okamoto ◽  
Kazuhiko Yamada ◽  
...  
Keyword(s):  
Phase Ii ◽  
Advanced Nsclc ◽  
Phase Ii Trial ◽  
Locally Advanced ◽  
Randomized Phase Ii ◽  
Locally Advanced Nsclc

A randomized, multicenter phase II study investigating additional weekly cetuximab to concurrent chemoradiotherapy in locally advanced non-small cell lung carcinoma: Reporting on the efficacy.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 7019-7019 ◽  
Author(s):  
Michel M van den Heuvel ◽  
Andrew D. Vincent ◽  
Wilma Uyterlinde ◽  
Joachim Aerts ◽  
Fredirike Koppe ◽  
...  
Keyword(s):  
Phase Ii ◽  
Concurrent Chemoradiotherapy ◽  
Advanced Nsclc ◽  
Phase Ii Study ◽  
Small Cell Lung Carcinoma ◽  
Locally Advanced ◽  
High Dose ◽  
Cell Lung Carcinoma ◽  
Multicenter Phase ◽  
Locally Advanced Nsclc

7019 Background: Modest benefits from concurrent chemoradiotherapy (CRT) in patients with locally advanced NSCLC warrant more effective treatment regimen. Cetuximab, a monoclonal antibody against the epidermal growth factor receptor has shown activity in NSCLC. Feasibility data and toxicity have been published previously. We report treatment outcome of a multicenter phase II study of the combination of high dose accelerated RT and daily dose cisplatin with or without weekly cetuximab. Methods: Patients with locally advanced NSCLC received accelerated RT (66 Gy in 24 fractions) and concurrent daily cisplatin (6 mg/m2) with (Arm A) or without (Arm B) additional weekly cetuximab (400 mg/m2 loading dose one week prior to the RT start followed by weekly 250 mg/m2). The Objective Local Response Control (OLRC) was determined at 6 and 24 weeks after treatment using response evaluation criteria in solid tumours criteria. Results: Between Feb 2009 and May 2011, 102 patients were included. Median follow-up was 13 months. Patients and tumor characteristics are shows in the Table. Stage distribution was: II (8%), IIIa (51%), and IIIb (40%). The CRT was well tolerated. The OLRC at 24 weeks was 79% in Arm A and 80% in Arm B. The one-year progression free survival and overall survival were 58% (45%-76%) and 76% (64%-91%) for Arm A and 49% (35%-68%) and 72% (58%-89%) for Arm B respectively. Conclusions: The addition of cetuximab to low dose cisplation CRT does not improve OLRC in an unselected patient cohort but data on longterm disease control and survival are to be awaited. [Table: see text]

O-266 Sequential versus sequential and simultaneous chemoradiotherapy in locally advanced NSCLC: A randomized phase II multicenter trial (CT/RT 99/97)

Lung Cancer ◽  
2003 ◽  
Vol 41 ◽  
pp. S77-S78
Author(s):  
Michael P. Flentje ◽  
Rudolf M. Huber ◽  
Anneliese Friedrich ◽  
Hildegard Gosse ◽  
Stephan Mose ◽  
...  
Keyword(s):  
Phase Ii ◽  
Advanced Nsclc ◽  
Locally Advanced ◽  
Multicenter Trial ◽  
Randomized Phase Ii ◽  
Locally Advanced Nsclc
Sign in / Sign up

Export Citation Format

Share Document